• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Noopur Raje, MD

Publications

  • Görgün GT, Whitehill G, Anderson JL, Hideshima T, Maguire C, Laubach J, Raje N, Munshi NC, Richardson PG, Anderson KC.Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans.Blood. 2013 Apr 11;121(15):2975-87.
    23321256
  • Pozzi S, Fulciniti M, Yan H, Vallet S, Eda H, Patel K, Santo L, Cirstea D, Hideshima T, Schirtzinge L, Kuhstoss S, Anderson KC, Munshi N, Scadden D, Kronenberg HM, Raje N.In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma.Bone. 2013 Apr;53(2):487-96.
    23333523
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Illizaliturri F, Huff CA, Kassim A, Krishnan AY, Liedtke M, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Weber D, Yahalom J, Yunus F, Shead DA, Kumar R.Multiple myeloma, version 1.2013.J Natl Compr Canc Netw. 2013 Jan 1;11(1):11-7.
    23307977
  • Mahindra A, Pozzi S, Raje N.Clinical trials of bisphosphonates in multiple myeloma.Clin Adv Hematol Oncol. 2012 Sep;10(9):582-7.
    23073123
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Cohen AD, Devine S, Djulbegovic B, Faber EA, Gasparetto C, Hernandez-Ilizaliturri F, Huff CA, Kassim A, Krishnan AY, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Treon SP, Tricot G, Weber DM, Yahalom J, Yunus F, Kumar R, Shead DA.Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma, Version 2.2013.J Natl Compr Canc Netw. 2012 Oct 1;10(10):1211-1219.
    23054875
  • Yee AJ, Raje NS.Denosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patients.Clin Interv Aging. 2012;7:331-8.
    22977302
  • Singh AV, Bandi M, Raje N, Richardson P, Palladino MA, Chauhan D, Anderson KC.A novel vascular disrupting agent plinabulin triggers JNK-mediated apoptosis and inhibits angiogenesis in multiple myeloma cells.Blood. 2011 Mar 31.
    21454451
  • Santo L, Hideshima T, Cirstea D, Bandi M, Nelson EA, Gorgun G, Rodig SJ, Vallet S, Pozzi S, Patel K, Unitt CL, Squires MS, Hu Y, Chauhan D, Mahindra A, Munshi NC, Anderson KC, Raje NS.Anti-myeloma activity of a multi targeted kinase inhibitor, AT9283, via potent Aurora Kinase and STAT3 inhibition either alone or in combination with lenalidomide.Clin Cancer Res. 2011 Mar 23.
    21430070
  • Raje N, Roodman GD.Advances in the biology and treatment of bone disease in multiple myeloma.Clin Cancer Res. 2011 Mar 15;17(6):1278-86.
    21411443
  • Singh AV, Bandi M, Aujay MA, Kirk CJ, Hark DE, Raje N, Chauhan D, Anderson KC.PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo.British Journal of Haematology. 2011 Jan;152(2):155-63.
    21114484
  • Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC.A novel orally active proteasome inhibitor ONX 0912 trigger in vitro and in vivo cytotoxicity in multiple myeloma.Blood. 2010 Dec 2;116(23):4906-15.
    20805366
  • Görgün G, Calabrese E, Soydan E, Hideshima T, Perrone G, Bandi M, Cirstea D, Santo L, Hu Y, Tai YT, Nahar S, Mimura N, Fabre C, Raje N, Munshi N, Richardson P, Anderson KC.Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma.Blood. 2010 Oct 28;116(17):3227-37.
    20651070
  • Raje N, Vallet S.Sotatercept, a soluble activin receptor type 2A IgG-Fc fusion protein for the treatment of anemia and bone loss.Curr Opin Mol Ther. 2010 Oct;12(5):586-97.
    20886391
  • Heher EC, Goes NB, Spitzer TR, Raje NS, Humphreys BD, Anderson KC, Richardson PG.Kidney disease associated with plasma cell dyscrasias.Blood. 2010 Sep 2;116(9):1397-404. Review.
    20462963
  • Ikeda H, Hideshima T, Fulciniti M, Perrone G, Mimura N, Yasui H, Okawa Y, Kiziltepe T, Santo L, Vallet S, Cirstea D, Calabrese E, Gorgun G, Raje NS, Richardson P, Munshi NC, Lannutti BJ, Puri KD, Giese NA, Anderson KC.PI3K/p110{delta} is a novel therapeutic target in multiple myeloma.Blood. 2010 Sep 2;116(9):1460-8.
    20505158
  • Vallet S, Smith MR, Raje N.Novel bone-targeted strategies in oncology.Clin Cancer Res. 2010 Aug 15;16(16):4084-93.
    20643782
  • Richardson PG, Weller E, Lonial S, Jakubowiak AJ, Jagannath S, Raje NS, Avigan DE, Xie W, Ghobrial IM, Schlossman RL, Mazumder A, Munshi NC, Vesole DH, Joyce R, Kaufman JL, Doss D, Warren DL, Lunde LE, Kaster S, Delaney C, Hideshima T, Mitsiades CS, Knight R, Esseltine DL, Anderson KC.Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma.Blood. 2010 Aug 5;116(5):679-86.
    20385792
  • Görgün G, Calabrese E, Hideshima T, Ecsedy J, Perrone G, Mani M, Ikeda H, Bianchi G, Hu Y, Cirstea D, Santo L, Tai YT, Nahar S, Zheng M, Bandi M, Carrasco RD, Raje N, Munshi N, Richardson P, Anderson KC.A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma.Blood. 2010 Jun 24;115(25):5202-13.
    20382844
  • Hideshima T, Mitsiades C, Ikeda H, Chauhan D, Raje N, Gorgun G, Hideshima H, Munshi NC, Richardson PG, Carrasco DR, Anderson KC.A proto-oncogene Bcl-6 is upregulated in the bone marrow microenvironment in multiple myeloma cells.Blood. 2010 May 6;115(18):3772-5.
    20228272
  • Cirstea D, Hideshima T, Rodig S, Santo L, Pozzi S, Vallet S, Ikeda H, Perrone G, Gorgun G, Patel K, Desai N, Sportelli P, Kapoor S, Vali S, Mukherjee S, Munshi NC, Anderson KC, Raje N.Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.Mol Cancer Ther. 2010 Apr;9(4):963-75.
    20371718
  • Vallet S, Mukherjee S, Vaghela N, Hideshima T, Fulciniti M, Pozzi S, Santo L, Cirstea D, Patel K, Sohani AR, Guimaraes A, Xie W, Chauhan D, Schoonmaker JA, Attar E, Churchill M, Weller E, Munshi N, Seehra JS, Weissleder R, Anderson KC, Scadden DT, Raje N.Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease.Proc Natl Acad Sci U S A. 2010 Mar 16;107(11):5124-9.
    20194748
  • Mahindra A, Cirstea D, Raje N.Novel therapeutic targets for multiple myeloma.Future Oncol. 2010 Mar;6(3):407-18. Review.
    20222797
  • Ropper AH, Raje NS, Lawrimore TM, Camelo-Piragua S, Sohani AR.Case records of the Massachusetts General Hospital. Case 7-2010. A 49-year-old man with peripheral neuropathy and ascites.N Engl J Med. 2010 Mar 11;362(10):929-40.
    20220188
  • Fonseca R, Richardson P, Giralt S, Lonial S, Rajkumar SV, Stewart AK, Bensinger W, Somlo G, Vescio R, Mikhael J, Reeder C, Tiedemann R, Tricot G, Rifkin R, Shaughnessy J, Munshi N, Raje N, Ghobrial I, Laubach J, Schlossman R, Treon S, Mahindra A, Avigan D, Rosenblatt J, Jagannath S, Niesvizky R, Landau H, Chen-Kiang S, Siegel DS, Zimmerman T, Mehta J, Vesole D, Rosen S, Hofmeister C, Lacy M, Dispenzieri A, Borrello I, Hayman SR, Kumar S, Buadi F, Dingli D, Russell S, Melissa Alsina MA, Fernandez H, Roy V, Pereira D, Stadtmauer E, Vij R, Jakubowiak A, Lentzsch S, Song K, Trudel S, Chen C, Reece D, Stewart D, Singhal S, Comenzo R, Gertz MA, Greipp PR, Durie B, Barlogie B, Anderson K, Dalton W, Coleman M, Novis S, Kyle RA.Conflicts of interest, authorship, and disclosures in industry-related scientific publications.Mayo Clin Proc. 2010 Feb;85(2):197-9; author reply 201-4.
    20118399
  • Cirstea D, Vallet S, Raje N.Future novel single agent and combination therapies.Cancer J.;15(6):511-8.
    20010171
  • Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima T, Buon L, Clynes M, O'Gorman P, Richardson PG, Mitsiades CS, Anderson KC, Mitsiades N.Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib.Clin Cancer Res. 2009 Dec 1;15(23):7153-60.
    19934289
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):947-60. Review.
    19878638
  • Anderson KC, Alsina M, Bensinger W, Biermann JS, Chanan-Khan A, Cohen AD, Devine S, Djulbegovic B, Gasparetto C, Huff CA, Jagasia M, Medeiros BC, Meredith R, Raje N, Schriber J, Singhal S, Somlo G, Stockerl-Goldstein K, Tricot G, Vose JM, Weber D, Yahalom J, Yunus F, .NCCN clinical practice guidelines in oncology: multiple myeloma.J Natl Compr Canc Netw. 2009 Oct;7(9):908-42.
    19878637
  • Laubach JP, Mitsiades CS, Mahindra A, Schlossman RL, Hideshima T, Chauhan D, Carreau NA, Ghobrial IM, Raje N, Munshi NC, Anderson KC, Richardson PG.Novel therapies in the treatment of multiple myeloma.J Natl Compr Canc Netw..
  • Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, Bianchi G, Podar K, Tai YT, Mitsiades C, Raje N, Jaye DL, Kumar SK, Richardson P, Munshi N, Anderson KC.Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target.Cancer Cell. 2009 Oct 6;16(4):309-23.
    19800576
  • Dutta-Simmons J, Zhang Y, Gorgun G, Gatt M, Mani M, Hideshima T, Takada K, Carlson NE, Carrasco DE, Tai YT, Raje N, Letai AG, Anderson KC, Carrasco DR.Aurora kinase A is a target of Wnt/beta-catenin involved in multiple myeloma disease progression.Blood. 2009 Sep 24;114(13):2699-708.
    19652203
  • Pozzi S, Vallet S, Mukherjee S, Cirstea D, Vaghela N, Santo L, Rosen E, Ikeda H, Okawa Y, Kiziltepe T, Schoonmaker J, Xie W, Hideshima T, Weller E, Bouxsein ML, Munshi NC, Anderson KC, Raje N.High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties.Clin Cancer Res. 2009 Sep 15;15(18):5829-39.
    19737962
  • Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Podar K, Hideshima T, Bianchi G, Mitsiades C, Raje N, Tai Y-T, Jaye DL, Kumar SK, Schlossman R, Richardson P, Munshi N, Anderson KC.Functional Interaction of plasmacytoid dendritic cells with multiple myeloma cells: a novel therapeutic target.Cancer Cell..
  • Hideshima T,Ikeda H,Chauhan D,Okawa Y,Raje N,Podar K,Mitsiades C,Munshi NC,Richardson PG,Carrasco RD,Anderson KC.Bortezomib induces canonical NF-{kappa}B activation in multiple myeloma cells.Blood. 2009 Jul 30;114(5):1046-52.
    19436050
  • Fulciniti M,Tassone P,Hideshima T,Vallet S,Nanjappa P,Ettenberg SA,Shen Z,Patel N,Tai YT,Chauhan D,Mitsiades C,Prabhala R,Raje N,Anderson KC,Stover DR,Munshi NC.Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.Blood. 2009 Jul 9;114(2):371-9.
    19417213
  • Ikeda H, Hideshima T, Fulciniti M, Lutz RJ, Yasui H, Okawa Y, Kiziltepe T, Vallet S, Pozzi S, Santo L, Perrone G, Tai YT, Cirstea D, Raje NS, Uherek C, Dälken B, Aigner S, Osterroth F, Munshi N, Richardson P, Anderson KC.The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.Clin Cancer Res. 2009 Jun 15;15(12):4028-37.
    19509164
  • Hideshima T,Chauhan D,Kiziltepe T,Ikeda H,Okawa Y,Podar K,Raje N,Protopopov A,Munshi NC,Richardson PG,Carrasco RD,Anderson KC.Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.Blood. 2009 May 21;113(21):5228-36.
    19270264
  • Okawa Y,Hideshima T,Steed P,Vallet S,Hall S,Huang K,Rice J,Barabasz A,Foley B,Ikeda H,Raje N,Kiziltepe T,Yasui H,Enatsu S,Anderson KC.SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK.Blood. 2009 Jan 22;113(4):846-55.
    18948577
  • Baehring JM,Hochberg EP,Raje N,Ulrickson M,Hochberg FH.Neurological manifestations of Waldenstrom macroglobulinemia.Nat Clin Pract Neurol. 2008 Oct;4(10):547-56. Review.
    18813229
  • Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y, Shen Z, Raje N, Kiziltepe T, Ocio EM, Chauhan D, Tassone P, Munshi N, Campbell RM, Dios AD, Shih C, Starling JJ, Tamura K, Anderson KC.p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications.British Journal of Haematology. 2008 May;141(5):598-606.
    18397345
  • Okawa Y, Hideshima T, Ikeda H, Raje N, Vallet S, Kiziltepe T, Yasui H, Enatsu S, Pozzi S, Breitkreutz I, Cirstea D, Santo L, Richardson P, Anderson KC.Fatty acid synthase is a novel therapeutic target in multiple myeloma.British Journal of Haematology. 2008 May;141(5):659-71.
    18410446
  • Vallet S, Palumbo A, Raje N, Boccadoro M, Anderson KC.Thalidomide and lenalidomide: Mechanism-based potential drug combinations.Leuk Lymphoma. 2008 Apr 23:1-8. Review.
    18452080
  • Raje N, Woo SB, Hande K, Yap JT, Richardson PG, Vallet S, Treister N, Hideshima T, Sheehy N, Chhetri S, Connell B, Xie W, Tai YT, Szot-Barnes A, Tian M, Schlossman RL, Weller E, Munshi NC, Van Den Abbeele AD, Anderson KC.Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.Clin Cancer Res. 2008 Apr 15;14(8):2387-95.
    18413829
  • Dodson TB, Raje NS, Caruso PA, Rosenberg AE.Case records of the Massachusetts General Hospital. Case 9-2008. A 65-year-old woman with a nonhealing ulcer of the jaw.N Engl J Med. 2008 Mar 20;358(12):1283-91.
    18354107
  • Mukherjee S, Raje N, Schoonmaker JA, Liu JC, Hideshima T, Wein MN, Jones DC, Vallet S, Bouxsein ML, Pozzi S, Chhetri S, Seo YD, Aronson JP, Patel C, Fulciniti M, Purton LE, Glimcher LH, Lian JB, Stein G, Anderson KC, Scadden DT.Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice.J Clin Invest. 2008 Feb;118(2):491-504.
    18219387
  • Neri P, Kumar S, Fulciniti MT, Vallet S, Chhetri S, Mukherjee S, Tai Y, Chauhan D, Tassone P, Venuta S, Munshi NC, Hideshima T, Anderson KC, Raje N.Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model.Clin Cancer Res. 2007 Oct 1;13(19):5903-9.
    17908986
  • Breitkreutz I, Raab MS, Vallet S, Hideshima T, Raje N, Chauhan D, Munshi NC, Richardson PG, Anderson KC.Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma.British Journal of Haematology. 2007 Oct;139(1):55-63.
    17854307
  • Hideshima T, Catley L, Raje N, Chauhan D, Podar K, Mitsiades C, Tai YT, Vallet S, Kiziltepe T, Ocio E, Ikeda H, Okawa Y, Hideshima H, Munshi NC, Yasui H, Richardson PG, Anderson KC.Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells.British Journal of Haematology. 2007 Sep;138(6):783-91.
    17760810
  • Vallet S, Raje N, Ishitsuka K, Hideshima T, Podar K, Chhetri S, Pozzi S, Breitkreutz I, Kiziltepe T, Yasui H, Ocio EM, Shiraishi N, Jin J, Okawa Y, Ikeda H, Mukherjee S, Vaghela N, Cirstea D, Ladetto M, Boccadoro M, Anderson KC.MLN3897, a novel CCR1 inhibitor, impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts.Blood. 2007 Nov 15;110(10):3744-52.
    17715391
  • Kiziltepe T, Hideshima T, Ishitsuka K, Ocio EM, Raje N, Catley L, Li CQ, Trudel LJ, Yasui H, Vallet S, Kutok JL, Chauhan D, Mitsiades CS, Saavedra JE, Wogan GN, Keefer LK, Shami PJ, Anderson KC.JS-K, a GST-activated nitric oxide generator, induces DNA double strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.Blood. 2007 Jul 15;110(2):709-18.
    17384201
  • Wang EP, Kaban LB, Strewler GJ, Raje N, Troulis MJ.Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy.J Oral Maxillofac Surg. 2007 Jul;65(7):1328-31.
    17577497
  • Kiziltepe T, Hideshima T, Catley L, Raje N, Yasui H, Shiraishi N, Okawa Y, Ikeda H, Vallet S, Pozzi S, Ishitsuka K, Ocio EM, Chauhan D, Anderson KC.5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells.Mol Cancer Ther. 2007 Jun;6(6):1718-27.
    17575103
  • Podar K, Raab MS, Tonon G, Sattler M, Baril D, Zhang J, Tai YT, Yasui H, Raje N, Depinho RA, Hideshima T, Chauhan D, Anderson KC.Up-Regulation of c-Jun Inhibits Proliferation and Induces Apoptosis via Caspase-Triggered c-Abl Cleavage in Human Multiple Myeloma.Cancer Res. 2007 Feb 15;67(4):1680-1688.
    17308109
  • Yasui H, Hideshima T, Ikeda H, Ocio EM, Kiziltepe T, Vallet S, Okawa Y, Neri P, Sukhdeo K, Podar K, Chauhan D, Richardson PG, Raje N, Carrasco DR, Anderson KC.Novel etodolac analog SDX-308 (CEP-18082) induces cytotoxicity in multiple myeloma cells associated with inhibition of beta-catenin/TCF pathway.Leukemia. 2007 Mar;21(3):535-40.
    17268521
  • Yasui H, Hideshima T, Ikeda H, Jin J, Ocio EM, Kiziltepe T, Okawa Y, Vallet S, Podar K, Ishitsuka K, Richardson PG, Pargellis C, Moss N, Raje N, Anderson KC.BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth.Br J Haematol. 2007 Feb;136(3):414-23.
    17173546
  • Chauhan D, Neri P, Velankar M, Podar K, Hideshima T, Fulciniti M, Tassone P, Raje N, Mitsiades C, Mitsiades N, Richardson P, Zawel L, Tran M, Munshi N, Anderson KC.Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).Blood. 2007 Feb 1;109(3):1220-7.
    17032924
  • Hideshima T, Neri P, Tassone P, Yasui H, Ishitsuka K, Raje N, Chauhan D, Podar K, Mitsiades C, Dang L, Munshi N, Richardson P, Schenkein D, Anderson KC.MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo.Clin Cancer Res. 2006 Oct 1;12(19):5887-94.
    17020997
  • Raje N, Hideshima T, Anderson KC.Therapeutic use of immunomodulatory drugs in the treatment of multiple myeloma.Expert Rev Anticancer Ther. 2006 Sep;6(9):1239-47. Review.
    17020458
  • Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, Richardson P, Schlossman R, Ghobrial I, Raje N, Munshi N, Anderson KC.A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma.Oncogene. 2007 Apr 5;26(16):2374-80.
    17016430
  • Raje N, Kumar S, Hideshima T, Ishitsuka K, Yasui H, Chhetri S, Vallet S, Vonescu E, Shiraishi N, Kiziltepe T, Elford HL, Munshi NC, Anderson KC.Didox, a ribonucleotide reductase inhibitor, induces apoptosis and inhibits DNA repair in multiple myeloma cells.Br J Haematol. 2006 Oct;135(1):52-61.
    16925573
  • Tai YT, Li XF, Breitkreutz I, Song W, Neri P, Catley L, Podar K, Hideshima T, Chauhan D, Raje N, Schlossman R, Richardson P, Munshi NC, Anderson KC.Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment.Cancer Res. 2006 Jul 1;66(13):6675-82.
    16818641
  • Neri P, Yasui H, Hideshima T, Tassone P, Raje N, Laurence CP, Ishitsuka K, Blotta S, Kiziltepe T, Ocio EM, Fulciniti M, Kanekal S, Elliott GT, Munshi NC, Anderson KC.In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells.Br J Haematol. 2006 Jul;134(1):37-44.
    16803565
  • Kumar S, Raje N, Hideshima T, Ishitsuka K, Podar K, Le Gouille S, Chauhan D, Richardson P, Munshi NC, Anderson K.FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma.Br J Haematol. 2006 Mar;132(6):698-704.
    16487170
  • Hideshima T, Catley L, Yasui H, Ishitsuka K, Raje N, Mitsiades C, Podar K, Munshi NC, Chauhan D, Richardson PG, Anderson KC.Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells.Blood. 2006 May 15;107(10):4053-62.
    16418332
  • Roccaro AM, Hideshima T, Raje N, Kumar S, Ishitsuka K, Yasui H, Shiraishi N, Ribatti D, Nico B, Vacca A, Dammacco F, Richardson PG, Anderson KC.Bortezomib mediates antiangiogenesis in multiple myeloma via direct and indirect effects on endothelial cells.Cancer Res. 2006 Jan 1;66(1):184-91.
    16397231
  • Yasui H, Hideshima T, Raje N, Roccaro AM, Shiraishi N, Kumar S, Hamasaki M, Ishitsuka K, Tai YT, Podar K, Catley L, Mitsiades CS, Richardson PG, Albert R, Brinkmann V, Chauhan D, Anderson KC.FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.Cancer Res. 2005 Aug 15;65(16):7478-84.
    16103102
  • Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Podar K, Le Gouill S, Shiraishi N, Yasui H, Roccaro AM, Tai YZ, Chauhan D, Fram R, Tamura K, Jain J, Anderson KC.Novel inosine monophosphate dehydrogenase inhibitor VX-944 induces apoptosis in multiple myeloma cells primarily via caspase-independent AIF/Endo G pathway.Oncogene. 2005 Sep 1;24(38):5888-96.
    15940263
  • Ishitsuka K, Hideshima T, Hamasaki M, Raje N, Kumar S, Hideshima H, Shiraishi N, Yasui H, Roccaro AM, Richardson P, Podar K, Le Gouill S, Chauhan D, Tamura K, Arbiser J, Anderson KC.Honokiol overcomes conventional drug resistance in human multiple myeloma by induction of caspase-dependent and -independent apoptosis.Blood. 2005 Sep 1;106(5):1794-800.
    15870175
  • Kumar S, Raje N, Hideshima T, Ishitsuka K, Roccaro A, Shiraishi N, Hamasaki M, Yasui H, Munshi NC, Richardson P, Figg WD, Anderson KC.Antimyeloma activity of two novel N-substituted and tetraflourinated thalidomide analogs.Leukemia. 2005 Jul;19(7):1253-61.
    15858615
  • Raje N, Kumar S, Hideshima T, Roccaro A, Ishitsuka K, Yasui H, Shiraishi N, Chauhan D, Munshi NC, Green SR, Anderson KC.Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma.Blood. 2005 Aug 1;106(3):1042-7.
    15827128
  • Yasui H, Hideshima T, Hamasaki M, Roccaro AM, Shiraishi N, Kumar S, Tassone P, Ishitsuka K, Raje N, Tai YT, Podar K, Chauhan D, Leoni LM, Kanekal S, Elliott G, Munshi NC, Anderson KC.SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma.Blood. 2005 Jul 15;106(2):706-12.
    15802527
  • Hideshima T, Chauhan D, Ishitsuka K, Yasui H, Raje N, Kumar S, Podar K, Mitsiades C, Hideshima H, Bonham L, Munshi NC, Richardson PG, Singer JW, Anderson KC.Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors.Oncogene. 2005 Apr 28;24(19):3121-9.
    15735676
  • Hamasaki M, Hideshima T, Tassone P, Neri P, Ishitsuka K, Yasui H, Shiraishi N, Raje N, Kumar S, Picker DH, Jacob GS, Richardson PG, Munshi NC, Anderson KC.Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo.Blood. 2005 Jun 1;105(11):4470-6.
    15705788
  • Hayashi T, Hideshima T, Akiyama M, Podar K, Yasui H, Raje N, Kumar S, Chauhan D, Treon SP, Richardson P, Anderson KC.Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical application.Br J Haematol. 2005 Jan;128(2):192-203.
    15638853
  • Le Gouill S, Podar K, Amiot M, Hideshima T, Chauhan D, Itshitsuka K, Kumar S, Raje N, Richardson PG, Harousseau JL, Anderson KC.VEGF induces MCL-1 upregulation and protects multiple myeloma cells against apoptosis.Blood. 2004 Nov 1;104(9):2886-92.
    15217829
  • Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT, Hamasaki M, Raje N, Hideshima H, Schreiner G, Nguyen AN, Navas T, Munshi NC, Richardson PG, Higgins LS, Anderson KC.p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells.Oncogene. 2004 Nov 18;23(54):8766-76.
    15480425
  • Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi NC, Stirling DI, Antin JH, Anderson KC.Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma.Blood. 2004 Dec 15;104(13):4188-93.
    15319277
  • Raje N, Hideshima T, Davies FE, Chauhan D, Treon SP, Young G, Tai YT, Avigan D, Gong J, Schlossman RL, Richardson P, Kufe DW, Anderson KC.Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma.Br J Haematol. 2004 May;125(3):343-52.
    15086415
  • Breyer ED, Howard S, Raje N, Allison S, Apkarian R, Brown WV, Strasters JK.Study of lipid and apolipoprotein binding interactions using vesicle affinity capillary electrophoresis.Anal Chem. 2003 Oct 1;75(19):5160-9.
    14708791
  • Hayashi T, Hideshima T, Akiyama M, Raje N, Richardson P, Chauhan D, Anderson KC.Ex vivo induction of multiple myeloma-specific cytotoxic T lymphocytes.Blood. 2003 Aug 15;102(4):1435-42.
    12714512
  • Raje N, Anderson KC.Thalidomide and immunomodulatory drugs as cancer therapy.Curr Opin Oncol. 2002 Nov;14(6):635-40.
    12409654
  • Brander C, Raje N, O'Connor PG, Davies F, Davis J, Chauhan D, Hideshima T, Martin J, Osmond D, Kedes DH, Walker BD, Scadden DT, Anderson KC.Absence of biologically important Kaposi sarcoma-associated herpesvirus gene products and virus-specific cellular immune responses in multiple myeloma.Blood. 2002 Jul 15;100(2):698-700.
    12091368
  • Raje N, Anderson KC.Multiple myeloma.Curr Treat Options Oncol. 2000 Apr;1(1):73-82.
    12057063
  • Finkel HE, Raje N.Case 27-2001: Waldenstrom's macroglobulinemia.N Engl J Med. 2002 Mar 7;346(10):784.
    11882742
  • Sirohi B, Powles R, Mehta J, Treleaven J, Raje N, Kulkarni S, Rudin C, Bhagwati N, Horton C, Saso R, Singhal S, Parikh R.The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients.Med Oncol. 2001;18(1):39-50.
    11778969
  • Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, Lin BK, Gupta D, Shima Y, Chauhan D, Mitsiades C, Raje N, Richardson P, Anderson KC.Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration.Blood. 2001 Jul 15;98(2):428-35.
    11435313
  • Davies FE, Raje N, Hideshima T, Lentzsch S, Young G, Tai YT, Lin B, Podar K, Gupta D, Chauhan D, Treon SP, Richardson PG, Schlossman RL, Morgan GJ, Muller GW, Stirling DI, Anderson KC.Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.Blood. 2001 Jul 1;98(1):210-6.
    11418482
  • Tai YT, Teoh G, Lin B, Davies FE, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Podar K, Anderson KC.Ku86 variant expression and function in multiple myeloma cells is associated with increased sensitivity to DNA damage.J Immunol. 2000 Dec 1;165(11):6347-55.
    11086072
  • Treon SP, Maimonis P, Bua D, Young G, Raje N, Mollick J, Chauhan D, Tai YT, Hideshima T, Shima Y, Hilgers J, von Mensdorff-Pouilly S, Belch AR, Pilarski LM, Anderson KC.Elevated soluble MUC1 levels and decreased anti-MUC1 antibody levels in patients with multiple myeloma.Blood. 2000 Nov 1;96(9):3147-53.
    11049996
  • Treon SP, Raje N, Anderson KC.Immunotherapeutic strategies for the treatment of plasma cell malignancies.Semin Oncol. 2000 Oct;27(5):598-613.
    11049026
  • Hideshima T, Chauhan D, Shima Y, Raje N, Davies FE, Tai YT, Treon SP, Lin B, Schlossman RL, Richardson P, Muller G, Stirling DI, Anderson KC.Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy.Blood. 2000 Nov 1;96(9):2943-50.
    11049970
  • Raje N, Anderson KC.Introduction: the evolving role of bisphosphonate therapy in multiple myeloma.Blood. 2000 Jul 15;96(2):381-3.
    10887095
  • Chauhan D, Pandey P, Hideshima T, Treon S, Raje N, Davies FE, Shima Y, Tai YT, Rosen S, Avraham S, Kharbanda S, Anderson KC.SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells.J Biol Chem. 2000 Sep 8;275(36):27845-50.
    10880513
  • Raje N, Kica G, Chauhan D, Zhang Y, Teoh G, Treon SP, Hideshima T, Deng JH, Gao SJ, Alsina M, Wally J, Davies FE, Tai YT, Pinkus GS, Pinkus JL, Skinner M, Comenzo RL, Anderson KC.Kaposi's sarcoma-associated herpesvirus gene sequences are detectable at low copy number in primary amyloidosis.Amyloid. 2000 Jun;7(2):126-32.
    10842716
  • Powles R, Sirohi B, Kulkarni S, Bhagwati N, Saso R, Raje N, Horton C, Singhal S, Mehta J, Treleaven J.Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma - a phase I/II feasibility and tolerance study of 17 patients.Bone Marrow Transplant. 2000 May;25(9):949-56.
    10800062
  • Hideshima T, Chauhan D, Teoh G, Raje N, Treon SP, Tai YT, Shima Y, Anderson KC.Characterization of signaling cascades triggered by human interleukin-6 versus Kaposi's sarcoma-associated herpes virus-encoded viral interleukin 6.Clin Cancer Res. 2000 Mar;6(3):1180-9.
    10741750
  • Tai YT, Teoh G, Shima Y, Chauhan D, Treon SP, Raje N, Hideshima T, Davies FE, Anderson KC.Isolation and characterization of human multiple myeloma cell enriched populations.J Immunol Methods. 2000 Feb 21;235(1-2):11-9.
    10675753
  • Teoh G, Tai YT, Urashima M, Shirahama S, Matsuzaki M, Chauhan D, Treon SP, Raje N, Hideshima T, Shima Y, Anderson KC.CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines.Blood. 2000 Feb 1;95(3):1039-46.
    10648420
  • Sumpter K, Powles RL, Raje N, Ramiah V, Kulkarni S, Treleaven J, Mainwaring PN.Oral idarubicin as a single agent therapy in patients with relapsed or resistant multiple myeloma.Leuk Lymphoma. 1999 Nov;35(5-6):593-7.
    10609797
  • Chauhan D, Hideshima T, Pandey P, Treon S, Teoh G, Raje N, Rosen S, Krett N, Husson H, Avraham S, Kharbanda S, Anderson KC.RAFTK/PYK2-dependent and -independent apoptosis in multiple myeloma cells.Oncogene. 1999 Nov 18;18(48):6733-40.
    10597281
  • Sirohi B, Powles R, Mehta J, Raje N, Kulkarni S, Ramiah V, Saso R, Horton C, Bhagwati N, Singhal S, Treleaven J.Complete remission rate and outcome after intensive treatment of 177 patients under 75 years of age with IgG myeloma defining a circumscribed disease entity with a new staging system.Br J Haematol. 1999 Dec;107(3):656-66.
    10583272
  • Raje N, Anderson K.Thalidomide--a revival story.N Engl J Med. 1999 Nov 18;341(21):1606-9.
    10564693
  • Chauhan D, Hideshima T, Treon S, Teoh G, Raje N, Yoshihimito S, Tai YT, Li W, Fan J, DeCaprio J, Anderson KC.Functional interaction between retinoblastoma protein and stress-activated protein kinase in multiple myeloma cells.Cancer Res. 1999 Mar 15;59(6):1192-5.
    10096546
  • Chauhan D, Bharti A, Raje N, Gustafson E, Pinkus GS, Pinkus JL, Teoh G, Hideshima T, Treon SP, Fingeroth JD, Anderson KC.Detection of Kaposi's sarcoma herpesvirus DNA sequences in multiple myeloma bone marrow stromal cells.Blood. 1999 Mar 1;93(5):1482-6.
    10029574
  • Raje N, Gong J, Chauhan D, Teoh G, Avigan D, Wu Z, Chen D, Treon SP, Webb IJ, Kufe DW, Anderson KC.Bone marrow and peripheral blood dendritic cells from patients with multiple myeloma are phenotypically and functionally normal despite the detection of Kaposi's sarcoma herpesvirus gene sequences.Blood. 1999 Mar 1;93(5):1487-95.
    10029575
  • Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC.Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone.Blood. 1999 Feb 15;93(4):1287-98.
    9949172
  • Cunningham D, Powles R, Malpas J, Raje N, Milan S, Viner C, Montes A, Hickish T, Nicolson M, Johnson P, Treleaven J, Raymond J, Gore M.A randomized trial of maintenance interferon following high-dose chemotherapy in multiple myeloma: long-term follow-up results.Br J Haematol. 1998 Jul;102(2):495-502.
    9695964
  • Powles R, Raje N, Milan S, Millar B, Shepherd V, Mehta J, Singhal S, Kulkarni S, Viner C, Gore M, Cunningham D, Treleaven J.Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.Bone Marrow Transplant. 1997 Sep;20(6):435-43.
    9313875
  • Raje N, Powles R, Kulkarni S, Milan S, Middleton G, Singhal S, Mehta J, Millar B, Viner C, Raymond J, Treleaven J, Cunningham D, Gore M.A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma.Br J Haematol. 1997 Apr;97(1):153-60.
    9136958
  • Raje N, Powles R, Horton C, Millar B, Shepherd V, Middleton G, Kulkarni S, Eisen T, Mehta J, Singhal S, Treleaven J.Comparison of marrow vs blood-derived stem cells for autografting in previously untreated multiple myeloma.Br J Cancer. 1997;75(11):1684-9.
    9184187
  • Singh J, Raje N.The rise of western medicine in India.Lancet. 1996 Dec 7;348(9041):1598.
    8950923
  • Duncan N, Hewetson M, Powles R, Raje N, Mehta J.An economic evaluation of peripheral blood stem cell transplantation as an alternative to autologous bone marrow transplantation in multiple myeloma.Bone Marrow Transplant. 1996 Dec;18(6):1175-8.
    8971391
  • Millar BC, Millar JL, Bell JB, Raje N, Milan S, Mehta J, Singhal S, Middleton GW, Sheperd V, Catovsky D, Powles RL.Role of CD34+ cells in engraftment after high-dose melphalan in multiple myeloma patients given peripheral blood stem cell rescue.Bone Marrow Transplant. 1996 Nov;18(5):871-8.
    8932839
  • Raje NS, Vaidya SJ, Kapoor G, Pai SK, Nair CN, Kurkure PA, Magrath IT, Advani SH.Low incidence of CNS relapse with cranial radiotherapy and intrathecal methotrexate in acute lymphoblastic leukemia.Indian Pediatr. 1996 Jul;33(7):556-60.
    8979564
  • Powles R, Raje N, Horton C, Mehta J, Singhal S, Hickish T, Viner C, Milan S, Treleaven J, Cunningham D.Comparison of interferon tolerance after autologous bone marrow or peripheral blood stem cell transplants for myeloma patients who have responded to induction therapy.Leuk Lymphoma. 1996 May;21(5-6):421-7.
    9172806
  • Singhal S, Powles R, Milan S, Raje N, Viner C, Treleaven J, Raymond J, Cunningham D, Mehta J.Kinetics of paraprotein clearance after autografting for multiple myeloma.Bone Marrow Transplant. 1995 Oct;16(4):537-40.
    8528169
  • Powles R, Raje N, Cunningham D, Malpas J, Milan S, Horton C, Mehta J, Singhal S, Viner C, Treleaven J.Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.Stem Cells. 1995 Aug;13 Suppl 2:114-7.
    8520498
  • Parikh PM, Badrinath Y, Dhond S, Kulkarni S, Dhar AK, Raje N, Saikia TK, Bharbhaya S, Gopal R, Kurkure PA.Evaluating efficiency of bone marrow harvest and its manipulation--role of CD 34 positivity.J Assoc Physicians India. 1995 Jul;43(7):470-2.
    8713220
  • Raje N, Pai S, Vaidya S, Gopal R, Parikh P, Saikia T, Pai V, Nadkarni K, Advani IM.Adult acute lymphoblastic leukemia: results of an aggressive regimen in India.Leuk Lymphoma. 1994 Jul;14(3-4):285-90.
    7950917
  • Raje NS, Rao SR, Iyer RS, Kelkar RS, Pai SK, Nair CN, Kurkure PA, Magrath IT, Advani SH.Infection analysis in acute lymphoblastic leukemia: a report of 499 consecutive episodes in India.Pediatr Hematol Oncol. 1994 May-Jun;11(3):271-80.
    8060811
  • Shah RV, Jambhekar NA, Rana DN, Raje NS, Albuqurque KV, Mistry RC, Desai PB, Advani SH.Melanotic neuroectodermal tumor of infancy: report of a case with ganglionic differentiation.J Surg Oncol. 1994 Jan;55(1):65-8.
    8289457
  • Raje NS, Rao SR, Vaidya SJ, Shah RV, Nair CN, Pai SK, Kurkure PA, Pande SC, Desai PB, Advani SH.Response with combined modality treatment in childhood rhabdomyosarcoma.J Surg Oncol. 1993 Dec;54(4):243-5.
    8255086